Search
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: APIXABAN EG, APIXABAN 5.0 MG TABLETA RECUBIERTAAvelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. … [A261496] Avelumab was first approved by the FDA on March 23, 2017.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: BAVENCIO 200 MG/10 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 FLAKON, BAVENCIO 200 mg/10mL concentrate for solution for infusionDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesProducts: TAFINLAR® 50 MG CÁPSULAS DURAS, TAFINLAR 50 MG KAPSUL, 20 ADETEtomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalImidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
Categories: Adrenergic alpha-2 Receptor Agonists, Heterocyclic Compounds, 1-RingSynonyms: (R)-(+)-1-(α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester, (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylateDicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.
Synonyms: 2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate, Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl esterMixtures: แอนพัส 520, AXCEL DICYCLOMINE-S SYRUPNitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedioneModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalNarcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesSynonyms: 2-((diphenylmethyl)sulfinyl)acetamideEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: EBASTINA EG, PINAVALT® 10 MG TABLETASRECUBIERTASDalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalIt is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. … LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women.
Products: FRAGMIN 2500 U.I/ML (ANTI-XA) VIAL DE 4 ML, -liq 2500 Iu(anti-XA)/mlDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalDaratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
Products: DARZALEX 400 MG/20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, DARZALEX 100 MG/5 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE